Please login to the form below

Not currently logged in
Email:
Password:

Roche's Avastin cuts progression of aggressive brain cancer

Supports potential new indication for oncology medicine

Roche Avastin

A new study of Roche's Avastin has shown the drug can extend progression-free survival (PFS) by more than four months when added onto standard therapy for an aggressive form of brain cancer.

The AVAglio trial found that adding Avastin (bevacizumab) to radiation and temozolomide chemotherapy reduced the risk of cancer progression by 36 per cent, extending PFS from 6.2 months with placebo to 10.6 months, in newly-diagnosed glioblastoma patients.

Roche's drug also had significant benefits on health-related quality of life measures - such as allowing patients to live independently for longer - and reduced use of concomitant therapies such as corticosteroids.

Avastin is already approved in Europe to treat colorectal cancer, breast cancer, lung cancer, kidney cancer and ovarian cancer, and is available in the US for colorectal cancer, non-small cell lung cancer and kidney cancer and also as a monotherapy for glioblastoma that has progressed despite prior treatment.

"People with newly diagnosed glioblastoma have few treatment options and need new medicines," said Hal Barron, Roche's chief medical officer and head of global product development, adding the plans to discuss the results with regulatory authorities.

Generic versions of temozolomide currently dominate the market, but prognosis for patients remains poor, particularly for those with glioblastoma.

Decision Resources has predicted that Avastin will help drive the market for glioblastoma to $1.8bn in 2017 among the seven largest pharma markets, although it believes the drug is already used quite extensively off-label.

Other therapies for glioblastoma coming through the pipeline include Celldex Therapeutics immunotherapy rindopepimut (CDX-110) - formerly partnered with Pfizer - and Merck Serono's integrin inhibitor cilengitide, both of which are in phase III development.

Glioblastomas are the most common and deadliest type of primary brain tumour, afflicting an estimated 10,000 patients each year in European Union (EU) member countries.

19th November 2012

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hamell

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

Latest intelligence

NEW EU DATA PROTECTION REGULATION POISED TO CHANGE DATA PRIVACY LANDSCAPE
NEW EU DATA PROTECTION REGULATION POISED TO CHANGE DATA PRIVACY LANDSCAPE The bold digital clock featured on the EUGDPR (EU General Data Protection Regulation)1 website indicates – to the second...
Health knowledge: Why is it so important?
Health knowledge plays an important role in population health, but by itself is rarely enough to prompt a change in the behaviours that cause the risks....
Personas: a top tool for personalising pharma marketing campaigns
Healthcare customers are calling for greater personalisation in care from providers. Here, we explain why personas are the top tool for ensuring your brand meets this need efficiently and effectively....

Infographics